Tscan Retained Earnings from 2010 to 2025

TCRX Stock

USD 1.52 0.07 4.83%

Tscan Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Tscan Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2010-12-31

Previous Quarter

-375.1 M

Current Value

-356.3 M

Quarterly Volatility

125.6 M

Credit Downgrade

Yuan Drop

Covid

Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 8.8 M, Interest Income of 12.7 M or Depreciation And Amortization of 3.6 M, as well as many indicators such as Price To Sales Ratio of 86.63, Dividend Yield of 0.0 or PTB Ratio of 1.48. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.

Check out the analysis of Tscan Therapeutics Correlation against competitors.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Tscan Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Tscan Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (375.1 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Tscan Retained Earnings Regression Statistics

	Arithmetic Mean	(90,447,762)
	Geometric Mean	40,561,318
	Coefficient Of Variation	(138.85)
	Mean Deviation	97,166,548
	Median	(17,406,000)
	Standard Deviation	125,589,115
	Sample Variance	15772.6T
	Range	357.7M
	R-Value	(0.79)
	Mean Square Error	6325.7T
	R-Squared	0.63
	Significance	0.0003
	Slope	(20,865,816)
	Total Sum of Squares	236589.4T

Tscan Retained Earnings History

	2025	-356.3 M
	2024	-375.1 M
	2023	-247.6 M
	2022	-158.4 M
	2021	-92.2 M
	2020	-43.5 M

Other Fundumenentals of Tscan Therapeutics

Retained Earnings Total Equity

Tscan Therapeutics Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Property Plant Equipment	Common Stock	Capital Surpluse	Long Term Debt	Short Long Term Debt
Total Assets		0.93	0.88	0.78	-0.64	-0.92	0.85	0.69	0.94	0.99	0.99	0.86	0.73	0.99	0.79	0.31	-0.54
Total Stockholder Equity	0.93		0.94	0.77	-0.79	-0.94	0.76	0.53	1.0	0.93	0.93	0.79	0.73	0.93	0.81	0.48	-0.74
Net Tangible Assets	0.88	0.94		0.74	-0.81	-0.8	0.66	0.33	0.93	0.88	0.88	0.84	0.73	0.87	0.58	0.28	-0.51
Current Deferred Revenue	0.78	0.77	0.74		-0.68	-0.74	0.83	0.48	0.76	0.8	0.76	0.68	0.96	0.79	0.58	0.24	-0.46
Net Debt	-0.64	-0.79	-0.81	-0.68		0.59	-0.47	0.03	-0.75	-0.72	-0.72	-0.39	-0.62	-0.62	-0.58	-0.53	0.56
Retained Earnings	-0.92	-0.94	-0.8	-0.74	0.59		-0.85	-0.76	-0.96	-0.91	-0.9	-0.79	-0.71	-0.94	-0.89	-0.51	0.8
Accounts Payable	0.85	0.76	0.66	0.83	-0.47	-0.85		0.78	0.78	0.82	0.79	0.77	0.88	0.82	0.79	0.46	-0.57
Total Liab	0.69	0.53	0.33	0.48	0.03	-0.76	0.78		0.57	0.62	0.6	0.65	0.48	0.71	0.69	0.21	-0.46
Net Invested Capital	0.94	1.0	0.93	0.76	-0.75	-0.96	0.78	0.57		0.93	0.93	0.82	0.73	0.94	0.81	0.47	-0.75
Total Current Assets	0.99	0.93	0.88	0.8	-0.72	-0.91	0.82	0.62	0.93		1.0	0.78	0.72	0.98	0.81	0.35	-0.55
Net Working Capital	0.99	0.93	0.88	0.76	-0.72	-0.9	0.79	0.6	0.93	1.0		0.77	0.68	0.97	0.81	0.36	-0.55
Short Term Debt	0.86	0.79	0.84	0.68	-0.39	-0.79	0.77	0.65	0.82	0.78	0.77		0.72	0.86	0.5	0.05	-0.37
Property Plant Equipment	0.73	0.73	0.73	0.96	-0.62	-0.71	0.88	0.48	0.73	0.72	0.68	0.72		0.72	0.54	0.3	-0.47
Common Stock	0.99	0.93	0.87	0.79	-0.62	-0.94	0.82	0.71	0.94	0.98	0.97	0.86	0.72		0.78	0.27	-0.56
Capital Surpluse	0.79	0.81	0.58	0.58	-0.58	-0.89	0.79	0.69	0.81	0.81	0.81	0.5	0.54	0.78		0.77	-0.83
Long Term Debt	0.31	0.48	0.28	0.24	-0.53	-0.51	0.46	0.21	0.47	0.35	0.36	0.05	0.3	0.27	0.77		-0.81
Short Long Term Debt	-0.54	-0.74	-0.51	-0.46	0.56	0.8	-0.57	-0.46	-0.75	-0.55	-0.55	-0.37	-0.47	-0.56	-0.83	-0.81

Click cells to compare fundamentals

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-375.1 M	-356.3 M
Retained Earnings Total Equity	-142.5 M	-149.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC